Fulgent Genetics Acquires Inform Diagnostics from Avista Capital Partners

Fulgent Genetics Acquires Fulgent Pharma

November 7, 2022

Biotechnology

Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.

Fulgent Genetics to Acquire Bako Diagnostics and StrataDx

December 22, 2025

Healthcare Services

Fulgent Genetics entered into a definitive agreement to acquire selected assets of Bako Diagnostics and to acquire StrataDx for a combined purchase price of approximately $55.5 million, subject to adjustments. The acquisitions are expected to close in the first half of 2026, subject to customary closing conditions and regulatory approvals.

OncoCyte Corporation Acquires Insight Genetics

January 10, 2020

Healthcare Services

OncoCyte Corporation agreed to acquire all outstanding capital stock of Insight Genetics, a privately held molecular diagnostics company, for approximately $12 million in cash and stock plus potential contingent payments. The acquisition adds Insight Genetics' IM Score immuno-oncology diagnostic test and a pharma-trial–capable CLIA/CAP lab to OncoCyte's portfolio to expand its capabilities in oncology diagnostics and pharma services.

InformedDNA Secures Growth Investment from TT Capital Partners, NovaQuest and Frist Cressey Ventures

December 13, 2019

Healthcare Services

InformedDNA, the U.S. leader in genetics services, has entered definitive agreements with TT Capital Partners, NovaQuest Capital Management, and Frist Cressey Ventures to receive a growth capital investment to scale its technology-enabled genetic services and expand its genetic counseling staff. Terms were not disclosed; InformedDNA will remain led by CEO David Nixon and has also secured a flexible credit facility from CIBC.

Versant Diagnostics Acquires Two Chicago-Area Pathology Practices

July 11, 2022

Healthcare Services

Versant Diagnostics, a PE-backed independent physician services company, acquired Pathology Consultants of Chicago and the operating assets of Elgin Laboratory Physicians to expand its footprint in the greater-Chicago market. The deals (Versant's third and fourth acquisitions in nine months) support the company's strategy to consolidate pathology practices and accelerate digital pathology conversion with growth capital backing from Iron Path Capital and financing support from Principal.

Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business

July 15, 2019

Healthcare Services

Interpace Diagnostics Group, Inc. acquired assets and certain liabilities comprising the Biopharma Services business of Cancer Genetics, Inc. for approximately $23.5 million, with the business continuing to operate from labs in Rutherford, New Jersey and Research Triangle Park, North Carolina. In conjunction with the transaction Ampersand Capital Partners invested $27 million in Interpace via convertible preferred stock to support the acquisition and Interpace’s growth in the clinical diagnostic and biopharma services markets.